Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3842MR)

This product GTTS-WQ3842MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3842MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13343MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ777MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ7836MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ8921MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ13109MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ8286MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ6040MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ7037MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Fab C225
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW